Bio-ReCell

Do you want to stay on top of everything in biotech but don’t have the time to read through many articles? We’ve got you covered with all the news from last week. 1. Immutep Mulls Filings for LAG-3 Drug After New Readout: Immutep's phase 2b trial results indicate that the LAG-3 inhibitor eftilagimod alfa (efti) significantly boosts the efficacy of Keytruda in patients with PD-L1-negative head and neck cancer, with a notable 35.5% objective response rate and a disease control rate of 57.7%. Learn more: https://lnkd.in/ePA-b3UY (pharmaphorum) 2. New Cellular Immunotherapy Shows Promise Against Solid Tumors in Phase II Trial: NIH researchers engineered patients' lymphocytes to produce receptors targeting their specific cancer cells. This personalized immunotherapy shrank tumors in metastatic colorectal cancer patients and prevented regrowth for up to seven months. Learn more: https://lnkd.in/eVAPGYxg (Inside Precision Medicine) 3. GLP1 and Harmine Therapy Reverses Diabetes in Mice by Regenerating Beta Cells: Researchers at Mount Sinai and City of Hope have developed a combination therapy of GLP1 and harmine that regenerates pancreatic beta cells, showing up to a 700% increase in human beta cells in mice, potentially reversing diabetes. Learn more: https://lnkd.in/e9iXZdza (Gen Eng News) 4. A Liver Immune Rheostat Regulates CD8 T Cell Immunity in Chronic HBV Infection: New research reveals that liver sinusoidal endothelial cells act as an immune rheostat, regulating CD8 T cell activation and function via the adenylyl cyclase-cAMP-PKA signaling axis, impacting chronic hepatitis B treatment. Learn more: https://lnkd.in/e4y9gFiX (Nature Portfolio) 5. uniQure’s Potential Breakthrough Gene Therapy for Huntington’s Delivers Positive Trial Results: Updated interim data from uniQure’s Phase I/II trial of AMT-130 gene therapy for Huntington’s disease shows a statistically significant slowing of disease progression and reduction in neurodegeneration biomarkers, offering hope for long-term clinical benefits. Learn more: https://lnkd.in/e5JBJ3sY (Inside Precision Medicine) Stay informed with our weekly biotech news roundup! #IndustryInsights #Biotechnology #HealthcareInnovation #GeneTherapy #Insights #CART

Recent FDA Approvals

The CAR-T therapy landscape has seen significant milestones with recent FDA approvals, marking critical advancements in the field: 1. Cilta-cel (Carvykti™): Approved for multiple myeloma, this therapy targets the B-cell maturation antigen (BCMA) and has shown impressive response rates in clinical trials. 2. Ide-cel (Abecma®): Also, for multiple myeloma, Ide-cel targets BCMA and represents a major breakthrough in the treatment of this challenging cancer.
 These approvals highlight the growing acceptance and validation of CAR-T therapies, providing new treatment options for patients and driving further innovation in the field. #cart #carttherapy #stemcells #celltherapy #biotech #biorecell #therapy #medicine

Struggling to stay informed about biotech advancements with your busy schedule? We've collected last week's news just for you. 1. Immix Biopharma's CAR-T Trial for Amyloidosis: Immix Biopharma administers its first CAR-T cell therapy to a U.S. patient with AL amyloidosis, marking a significant milestone in their Phase Ib/II clinical trial. Learn more: https://lnkd.in/ejmypvEC 2. Discovery of Rare T Cells by RIKEN Scientists: Researchers at RIKEN and Kyoto University identify rare helper T cells linked to immune disorders, offering new insights into conditions like multiple sclerosis and rheumatoid arthritis. Learn more: https://lnkd.in/ebHp8-2W 3. Cartesian's CAR-T Progress in Autoimmune Disease: Cartesian Therapeutics reports promising Phase 2 results for Descartes-08 in myasthenia gravis, though questions remain about the trial’s overall efficacy and statistical thresholds. Learn more: https://lnkd.in/exWaGQ7d 4. J&J and Legend's Carvykti in Multiple Myeloma: J&J and Legend Biotech announce that Carvykti, their CAR-T therapy, significantly extends overall survival in multiple myeloma patients, furthering its lead over competing treatments. Learn more: https://lnkd.in/eBwRjG4T 5. Whole Genome Sequencing in Pediatric Cancer Care: Whole genome sequencing at two English hospitals reveals treatment-changing information in approximately 7% of pediatric cancer cases, emphasizing the value of this advanced diagnostic tool. Learn more: https://lnkd.in/eqdcb8_s Follow us for more weekly updates. #IndustryInsights #Biotechnology #HealthcareInnovation #GeneTherapy #Insights #CART

Could CAR-T Therapy be a cure for solid tumours? While CAR-T therapy has shown great success in treating blood cancers, applying it to solid tumours presents unique challenges due to the complex tumour microenvironment. Recent advancements aim to overcome these barriers: 
1. Enhanced T-Cell Infiltration: Innovative biomaterials and engineering techniques are improving CAR-T cell infiltration into solid tumours. 2. Target Identification: Research is identifying new tumour-specific antigens to reduce off-target activity and increase efficacy. 3. Overcoming Immunosuppression: Modifying CAR-T cells to resist the immunosuppressive environment of solid tumours enhances their persistence and activity. These developments are paving the way for the application of CAR-T therapy in a broader range of cancers, offering new hope for patients with solid tumours. #cart #carttherapy #celltherapy #stemcells #biorecell #therapy #medicine

Do you wish to stay on top of everything in biotech but can't find the time to read through a bunch of articles? Worry no more. We've got you covered with all the news from last week. 1. Exsilio Therapeutics Launches with $82M Funding: Exsilio Therapeutics, focusing on redosable genomic medicines, launched with $82 million in Series A funding to develop RNA-based therapies for genetic disorders, cancers, and autoimmune diseases. (Precision Medicine Online) 2. Lyell's Two-Track Approach in CAR-T Trials: Following a patient death and adverse events, Lyell Immunopharma is adjusting its CAR-T dose escalation strategy in lung metastasis patients, highlighting the complexities of CAR-T in solid tumors. (Fierce Biotech) 3. Advanced Meditation's Impact on Consciousness: Research into advanced meditation is uncovering its potential to transform mental health and consciousness, offering new avenues for psychological well-being and therapeutic interventions. (Scientific American) 4. Chimeric Brain Organoids for Drug Response Studies: For the first time, 3D brain models containing cells from multiple donors have been developed, promising insights into individual drug responses and brain development variations. (Nature Portfolio) 5. Neuronal Senescence and Brain Aging: Studies reveal that senescence in neurons may drive brain aging, presenting both challenges and opportunities for developing therapies to address neurodegenerative diseases. (Science) Save time for the things you like doing instead of reading articles. Follow us, and we'll update you each week on the latest industry trends. #IndustryInsights #Biotechnology #HealthcareInnovation #GeneTherapy

Evolution of CAR-T Cells: From First to Fifth Generation CAR-T cell technology has evolved significantly since its inception. Here’s a look at the progression through its generations: 1. First Generation: Early CAR-T cells had limited efficacy and persistence due to the use of a single activation domain. 2. Second Generation: Addition of costimulatory domains (CD28 or 4-1BB) improved their survival and anti-tumor activity. 3. Third Generation: Combined multiple costimulatory domains, further enhancing functionality and longevity. 4. Fourth Generation (TRUCKs): Incorporated inducible cytokine production, improving the ability to modulate the tumor environment and activate innate immunity. 5. Fifth Generation: Introduced IL-2 receptor chains and advanced signaling pathways, enhancing CAR-T cell persistence and reducing the risk of exhaustion. These advancements have progressively improved the efficacy and safety of CAR-T therapies, making them more robust and effective. #CAR-T #Biotech #CancerResearch #Cancer #Therapy #Science #Medicine

New week, new industry insights. Take a look at what's making the headlines: 1. CAR-T in Autoimmune Diseases: New data show promise for CAR-T cell therapies in treating autoimmune diseases like lupus and myositis. Early trials reveal significant potential, with many patients experiencing long-term remission. However, challenges remain, including high costs and manufacturing complexities. (BioPharma Dive) 2. Parkinson’s Early Detection: Researchers have developed a blood test that predicts Parkinson’s disease up to seven years before symptoms appear. This test, which analyzes eight protein biomarkers, could revolutionize early treatment and protection of brain cells. (Inside Precision Medicine) 3. Measuring Forces in Embryonic Development: Advances in mechanobiology are enabling scientists to measure the physical forces that shape embryonic development. New tools like microdroplet sensors and Brillouin microscopy offer deeper insights into how cells organize and form tissues. (Nature Portfolio) 4. Thousand Brains Project: This project, funded by the Gates Foundation, aims to create AI that mimics the human neocortex. This initiative seeks to overcome current AI limitations and enhance robotics and healthcare applications by building AI based on cortical columns and sensorimotor learning. (IEEE Spectrum) 5. iPS Cell-Derived Therapy for GvHD: A clinical trial of iPS cell-derived mesenchymal stromal cells shows favorable long-term safety and efficacy for treating steroid-resistant graft-versus-host disease. This therapy offers a promising alternative to conventional treatments with a 60% survival rate at two years. (Nature Portfolio) To read more on these topics, click the links to the original articles in the comments section. #Biotech #AutoimmuneDisease #Parkinsons #EmbryonicDevelopment #AI #GvHD #MedicalInnovation #Healthcare #ResearchAndDevelopment

What is CAR-T Therapy? Chimeric Antigen Receptor T-cell (CAR-T) therapy is a groundbreaking form of immunotherapy that has shown remarkable success in treating certain types of cancer, particularly hematologic malignancies like leukemia and lymphoma. Here’s a basic rundown of how it works: 1. T-Cell Collection: The process starts with the extraction of T-cells from the patient's blood. 2. Genetic Modification: These T-cells are genetically engineered in the lab to express a chimeric antigen receptor (CAR) that targets specific proteins on cancer cells. 3. Cell Expansion: The modified T-cells are then multiplied to create millions of CAR-T cells. 4. Infusion: Finally, these CAR-T cells are infused back into the patient, where they seek out and destroy cancer cells. CAR-T therapy leverages the body's own immune system to fight cancer, making it a personalized and highly targeted treatment option. Stay tuned as we dive deeper into the latest advancements in CAR-T therapy in the coming posts.

Read through the insights of last week in biotech. 1. CRISPR's Promise and Challenges: Indian researchers' attempt to save Uditi Saraf with a groundbreaking gene-editing treatment underscores CRISPR's potential and the hurdles in treating rare diseases. Despite Uditi's passing, their efforts offer hope for future therapies. Learn more: https://lnkd.in/ejs_Mp4V (Nature Portfolio) 2. Prostate Cancer CAR T Breakthrough: City of Hope's new CAR T cell therapy shows promise for metastatic prostate cancer, advancing to Phase Ib trials. Combining CAR T with radiation aims to boost its effectiveness, marking significant progress in treating resistant cancers. Learn more: https://lnkd.in/eaGjuv2R (Inside Precision Medicine) 3. Pfizer's Gene Therapy Setback: Pfizer's phase 3 trial for Duchenne muscular dystrophy didn't improve motor function as hoped. While disappointing, insights gained will guide future treatment development. Learn more: https://lnkd.in/esZZ4siN (Fierce Pharma) 4. RNA Revolution: Emerging research highlights the vital role of noncoding RNAs in gene regulation, challenging old beliefs about DNA. This "RNA revolution" could lead to new cancer treatments and other disease therapies. Learn more: https://lnkd.in/ehbsN3TK (Scientific American) 5. Brainstem's Role in Immunity: Discoveries reveal the brainstem's crucial function in regulating body-wide inflammation, opening new treatment possibilities for inflammatory diseases like arthritis and IBD. Learn more: https://lnkd.in/e2YrrWCV (Quanta Magazine) Stay tuned for more insights every week. #Biotech #CRISPR #GeneTherapy #CancerResearch #RNARevolution #Immunology #MedicalInnovation #RareDiseases #BioReCell

Welcoming Our Strategic Board of Advisors to Slovenia! We were honored to host our esteemed advisors: Prof. Dr. Mark Lowdell, PhD, Dr. Paul Kemp, Joseph P. Taormino, PhD, Antonio Sfiligoj, and Prof. Dr. Stephen Minger, PhD. Their visit last week was incredibly productive. Our team had the chance to showcase our latest progress. Engaging in insightful discussions with them was invaluable. Their extensive experience and advice gave us fresh perspectives. They provided strategies to propel our research forward. The visit included a series of presentations by our dedicated researchers. A collaborative session over coffee and croissants followed. This allowed for meaningful interactions where our team members received personalized guidance. They found solutions to ongoing challenges and gained valuable insights. We are deeply grateful to our advisors. Their time, support, and commitment to advancing cell separation and activation technologies are invaluable. Their contributions help us pioneer novel solutions. They help us achieve our ambitious goals. Below are some highlights from their visit. #BioReCell #ResearchAndDevelopment #AdvisoryBoard #Innovation #CellSeparation #CellActivation #Biotech